SEATTLE, Sept. 4 -- Simvastatin/ezetimibe (Vytorin) may increase the risk of cancer after all, concluded a leading American biostatistician who dismissed as prematurely reassuring an analysis by ...

The updated AHA/ACC cholesterol management guidelines recommend moderate or high intensity statin therapy in patients over 75 years old with clinical atherosclerotic cardiovascular disease. According ...

(UPDATED) Elderly patients with stabilized acute coronary syndrome derive the biggest absolute bang for the buck from intensive lipid-lowering with ezetimibe and simvastatin combination therapy, ...

In a huge setback a study has found that the Simvastatin-Ezetimibe reduces risk of coronary artery disease (CAD), but does not slow its progression. The Simvastatin and Ezetimibe in Aortic Stenosis ...